Table 1 Characteristics of included studies
Included RCTs | Method of randomization | Number of patients (rLHtrFSH/rFSH) | Gn type and initial dosage (IU/d) | rLH protocol | Pretreament | Primary outcomes |
|---|---|---|---|---|---|---|
Sauer et al. 2004 [5] | Computer generated | 21/21 | r-hFSH 225 | r-hLH, 150 IU on stimulation day 7–10 | Oral contraceptive pretretment (0.15 mg desogestrel and 0.03 mg ethinyloestradiol) | Mean number of retrieved |
MII oocytes | ||||||
Griesinger et al. 2005 [6] | Sealed envelop | 61/65 | r-hFSH 150 | rLH, 75Â IU on day 2 of the natural cycle | None | Number of days of gonadotropin treatment |
Levi-Setti et al. 2006 [7] | Computer-generated list | 20/20 | r-hFSH 150 | rLH, 75Â IU when follicles reached the mean diameter of 14 and 15Â mm | Oral contraceptive ((Minulet; Wyeth, Aprilia-Latinia, Italy)) | Number of metaphase II oocytes retrieved |
Bosch et al. 2011 [14] | Computer-generated list | Aged <35 years:190/190; aged 36 to 39 years: 170/170 | Patients ≤ 35 years old: rFSH-alone group: rFSH 225 ;the rFSH + rLH group: rFSH 150; patients aged 36–39 years: rFSH-alone group: rFSH 300; rFSH + rLH group: rFSH 225 | rLH, 75 IU on stimulation day 1 | Oral contraceptive pill (0.030 mg ethinyl E2 and 3.0 mg drospirenone) | Implantation rate |
König et al. 2013 [15] | Sealed envelopes | 125/128 | r-hFSH, 225 IU | rLH, 150 IU on stimulation day 6 | None | Implantation rate; clinical pregnancy rate |